The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

Context International variations in the rates of kidney cancer (KC) are considerable. An
understanding of the risk factors for KC development is necessary to generate opportunities …

Clear cell renal cell carcinomas (ccRCCs) represent∼ 75% of RCC cases and account for
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …

Background The phase 3 CheckMate 214 trial demonstrated higher response rates and
improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line …

Molecular routes to metastatic dissemination are critical determinants of aggressive cancers.
Through in vivo CRISPR–Cas9 genome editing, we generated somatic mosaic genetically …

A complete chart of the chromatin regulatory elements of immune cells in patients with
cancer and their dynamic behavior is necessary to understand the developmental fates and …

Translocation renal cell carcinoma (tRCC) is a poorly characterized subtype of kidney
cancer driven by MiT/TFE gene fusions. Here, we define the landmarks of tRCC through an …

Molecular profiling of clear cell renal cell carcinoma (ccRCC) tumors of patients in a clinical
trial has identified distinct transcriptomic signatures with predictive value, yet data in non …

Background Among patients with advanced renal cell carcinoma (RCC), those with
sarcomatoid histology (sRCC) have the poorest prognosis. This analysis assessed the …

Immune checkpoint inhibitors have significantly transformed the treatment paradigm for
metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving …